Immune therapy with chemotherapy for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years
- Cervical cancer diagnosed at FIGO stage IB3 or IIA2 (locally advanced, not yet spread to distant organs)
- Confirmed squamous cell, adenocarcinoma, or adenosquamous cell type
- No prior chemotherapy, radiation, or immunotherapy for cancer
- Good overall health (able to perform light activities; ECOG score 0–1)
- Lymph nodes in pelvis and abdomen are small (under 1.5 cm on imaging)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs before standard treatment for locally advanced cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.